Want to see NMRA full AI Analyst Report?

Neumora Therapeutics, Inc. (NMRA) Price & Analysis

450 Followers

NMRA Stock Chart & Stats

$1.50

$0.18(12.08%)

At close: Jul 27 4:00 PM EDT

$1.50

$0.18(12.08%)

Day’s Range― - ―

52-Week Range$0.32 - $3.65

Previous CloseN/A

Volume485.06K

Average Volume (3M)2.22M

Market Cap

$72.96M

Enterprise Value$251.20M

Total Cash (Recent Filing)$116.83M

Total Debt (Recent Filing)$340.00K

Price to Earnings (P/E)―

Beta2.24

Next Earnings

Nov 04, 2026

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.23

Shares Outstanding187,895,900

10 Day Avg. Volume2,087,184

30 Day Avg. Volume2,216,349

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)2.82

Price to Sales (P/S)0.00

P/FCF Ratio-1.42

Enterprise Value/Market Cap3.44

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-50.16

Enterprise Value/Ebitda-1.21

Forecast

1Y Price Target

$5.00

Price Target Upside233.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.9

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Minimal LeverageVery low debt limits interest obligations and borrowing-related financial risk, giving Neumora more flexibility as it funds clinical development. This balance-sheet feature can help preserve strategic options during periods of uncertain trial outcomes, although it does not offset the company’s operating losses.

Cash RunwayManagement’s stated cash runway into the third quarter of 2027 provides time to advance programs and reach multiple clinical milestones without an immediate funding requirement. That runway supports development continuity and allows the company to execute its pipeline strategy over the next several quarters.

Clinical Pipeline BreadthA pipeline spanning obesity and cardiometabolic disease, Alzheimer’s agitation, and schizophrenia gives Neumora several potential avenues for clinical value creation. Multiple neuroscience programs diversify development opportunities and could improve the company’s prospects if clinical milestones support advancement.

Bears Say

Pre-revenue Business ModelNeumora has no commercial revenue base and continues to report substantial net losses, leaving its financial profile dependent on research progress rather than recurring product sales. Until a program reaches commercialization, the company lacks operating income to internally fund ongoing development.

Heavy Cash Burn And Shrinking EquityPersistent negative operating and free cash flow consumes capital while the sharp decline in equity reduces the company’s financial cushion. Continued development spending may require additional funding over time, creating dilution or financing pressure even though current debt remains minimal.

Nasdaq Listing RiskFailure to regain Nasdaq’s minimum bid-price compliance could lead to a transfer to the Capital Market or eventual delisting. The company is evaluating options including a reverse split, making listing continuity and related corporate actions an important ongoing risk.

Neumora Therapeutics, Inc. News

Neumora Therapeutics price target lowered to $3 from $4 at Mizuho

Mizuho lowered the firm’s price target on Neumora Therapeutics (NMRA) to $3 from $4 and keeps an Outperform...

2d ago

NMRA

Neumora Therapeutics Faces Nasdaq Minimum Bid Price Warning

Neumora Therapeutics, Inc. ( ($NMRA) ) has issued an update. On October 26, 2026, Neumora Therapeutics received notice...

3h ago

NMRA

Neumora CEO transition not a surprise, says H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao views the appointment of Josh Pinto as Neumora Therapeutics’s (NMRA) next CEO as...

2M ago

NMRA

Neumora Therapeutics reports Q2 EPS (23c), consensus (24c)

“We delivered another quarter of disciplined execution against our strategic priorities, advancing key programs across our pipeline and...

3M ago

NMRA

Neumora Therapeutics CEO Paul Berns to switch roles, Joshua Pinto to succeed

Neumora announced the appointment of Joshua Pinto as president and chief executive officer and a member of the...

3M ago

NMRA

Neumora Therapeutics Announces CEO Transition and Q2 Results

Neumora Therapeutics, Inc. ( ($NMRA) ) has shared an update. On August 14, 2026, Neumora Therapeutics reported second-quarter...

3M ago

NMRA

NMRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Neumora Therapeutics, Inc. (NMRA) is scheduled to report 2nd quarter earnings on 08/12/2026. Regarding Q2 estimates, Wall Street...

3M ago

NMRA

Neumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class Thesis

William Blair analyst Myles Minter has maintained their bullish stance on NMRA stock, giving a Buy rating today....

3M ago

NMRA

Neumora Maintained at Buy as NMRA-215 Advances Toward Phase 1; $5 Price Target Reaffirmed

Ami Fadia, an analyst from Needham, maintained the Buy rating on Neumora Therapeutics, Inc.. The associated price target...

3M ago

NMRA

Neumora advances NMRA-215 with positive toxicology results

Neumora Therapeutics, Inc. ( ($NMRA) ) just unveiled an announcement. On July 27, 2026, Neumora Therapeutics reported favorable...

3M ago

NMRA

Neumora Therapeutics reports pre-clinical toxicology results from NMRA-215 study

Neumora Therapeutics (NMRA) reported pre-clinical toxicology results from NMRA-215, a highly brain-penetrant, oral NLRP3 inhibitor in development for...

3M ago

NMRA

Neumora Therapeutics price target lowered to $5 from $7 at RBC Capital

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Neumora Therapeutics (NMRA) to $5 from $7...

4M ago

NMRA

Neumora Therapeutics price target lowered to $4 from $6 at Mizuho

Mizuho lowered the firm’s price target on Neumora Therapeutics (NMRA) to $4 from $6 and keeps an Outperform...

4M ago

NMRA

Neumora Therapeutics price target lowered to $5 from $8 at Needham

Needham analyst Ami Fadia lowered the firm’s price target on Neumora Therapeutics (NMRA) to $5 from $8 and...

5M ago

NMRA

NMRA FAQ

What was Neumora Therapeutics, Inc.’s price range in the past 12 months?

Neumora Therapeutics, Inc. lowest stock price was $0.32 and its highest was $3.65 in the past 12 months.

What is Neumora Therapeutics, Inc.’s market cap?

Neumora Therapeutics, Inc.’s market cap is $72.96M.

When is Neumora Therapeutics, Inc.’s upcoming earnings report date?

Neumora Therapeutics, Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 4 days.

How were Neumora Therapeutics, Inc.’s earnings last quarter?

Neumora Therapeutics, Inc. released its earnings results on Aug 14, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.01.

Is Neumora Therapeutics, Inc. overvalued?

According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neumora Therapeutics, Inc. pay dividends?

Neumora Therapeutics, Inc. does not currently pay dividends.

What is Neumora Therapeutics, Inc.’s EPS estimate?

Neumora Therapeutics, Inc.’s EPS estimate is -0.2.

How many shares outstanding does Neumora Therapeutics, Inc. have?

Neumora Therapeutics, Inc. has 187,895,900 shares outstanding.

What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?

Neumora Therapeutics, Inc. reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -7.514%.

Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?

Currently, no hedge funds are holding shares in NMRA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Neumora Therapeutics, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-242.28%

Trailing 12-Months

Asset Growth

-44.04%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Neumora Therapeutics, Inc. (NMRA) Earnings & Revenues

Historic Earnings Reports

NMRA Stock 12 Month Forecast

Average Price Target

$5.00

▲(233.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.55,1.0461538461538462,1.5423076923076924,2.0384615384615383,2.5346153846153845,3.0307692307692307,3.526923076923077,4.023076923076923,4.519230769230769,5.015384615384615,5.5115384615384615,6.007692307692308,6.503846153846154,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.55,0.8923076923076924,1.2346153846153847,1.5769230769230769,1.9192307692307693,2.2615384615384615,2.6038461538461535,2.9461538461538463,3.2884615384615383,3.630769230769231,3.973076923076923,4.315384615384615,4.657692307692307,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.55,0.7384615384615385,0.926923076923077,1.1153846153846154,1.303846153846154,1.4923076923076923,1.680769230769231,1.8692307692307695,2.057692307692308,2.246153846153846,2.434615384615385,2.6230769230769235,2.811538461538462,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.78,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.55,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >